EUCTR2009-017789-22-ATActive, not recruitingNot Applicable
A randomized, placebo-controlled study investigating the effects of moxaverine on ocular blood flow after oral administration in healthy subjects - MOXOPH3
rsapharm Arzneimittel GmbH0 sitesStarted: April 8, 2010Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Men and women aged between 18 and 35 years, nonsmokers
- •Body mass index between 16 and 30 kg/m²
- •Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- •Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
- •Normal ophthalmic findings, ametropia <6 dpt, anisometropia <2 dpt
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Regular use of medication, abuse of alcoholic beverages or drugs
- •Participation in a clinical trial in the 3 weeks preceding the study
- •Treatment in the previous 3 weeks with any drug
- •Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- •History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of the study drug
- •Blood donation during the previous 3 weeks
- •Presence of any ocular pathology that interferes with the aims of the present study
- •Hypersensitivity to moxaverine
- •Acute gastric bleeding, massive cerebral hemorrhage related to stroke
- •Women: pregnancy or lactation
Investigators
Similar Trials
Active, not recruiting
Phase 1
improvement of cognitive performance after administration of fampridina in patients with multiple sclerosisMedDRA version: 20.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMULTIPLE SCLEROSISEUCTR2013-002558-64-ITdipartimento di neurologia e psichiatria123
Not yet recruiting
Not Applicable
A micronutrient intervention for students experiencing stressAnxietyACTRN12620000551998niversity of Canterbury, School of Psychology, Speech, and Hearing120
Completed
Not Applicable
Investigating the effect of bilateral quadriceps NeuroMuscular Electrical Stimulation (NMES) on exercise capacity in patients with severe chronic obstructive pulmonary diseaseISRCTN15985261King College Hospital (UK)52
Terminated
Phase 2
Effectiveness of herbal formulations for stressStressAlternative and Complementary Medicine - Herbal remediesMental Health - AnxietyACTRN12623000287639Integria Healthcare (Australia) Pty Ltd.94
Completed
Not Applicable
Randomized, placebo-controlled study on the influence of Silica on stress-induced increased permeablity in patients with gastrointestinal symptomsK58Irritable bowel syndromeDRKS00009545STZ 1172 Gesundheitsförderung und Stoffwechselforschung30